Stipple Bio - About the company
Stipple Bio is a series A company based in Cambridge (United States), founded in 2021 by Aaron Ring and Aashish Manglik. It operates as a Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery. Stipple Bio has raised $109M in funding from investors like Andreessen Horowitz, RA Capital Management and Nextech Invest. The company has 161 active competitors, including 65 funded and 9 that have exited. Its top competitors include companies like Evotec, Insitro and DNAnexus.
Company Details
Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery. The platform technology enables single-cell profiling and target identification for ddrug discovery and development of cancer immunotherapy and others.
- Website
- stipple.bio
- Email ID
- *****@stipple.bio
Key Metrics
Founded Year
2021
Location
Cambridge, United States
Stage
Series A
Total Funding
$109M in 2 rounds
Latest Funding Round
Investors
Ranked
27th among 161 active competitors
Employee Count
13 as on Apr 30, 2026
Sign up to download Stipple Bio's company profile
Stipple Bio's funding and investors
Stipple Bio has raised a total funding of $109M over 2 rounds. Its first funding round was on Dec 20, 2024. Its latest funding round was a Series A round on Mar 31, 2026 for $*****. 6 investors participated in its latest round. Stipple Bio has 7 institutional investors.
Here is the list of recent funding rounds of Stipple Bio:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 31, 2026 | 6700116 | Series A | 5638284 | 6643606 | 3172263 | 7366348 |
Dec 20, 2024 | 6024405 | Series A | 9183241 | 1939875 | 3705989 | 8321551 |
Access funding benchmarks and valuations. Sign up today!View details of Stipple Bio's funding rounds and investors
Stipple Bio's founders and board of directors
Founder? Claim ProfileThe founders of Stipple Bio are Aaron Ring and Aashish Manglik.
Here are the details of Stipple Bio's key team members:
- Aaron Ring: Co-Founder of Stipple Bio and founder of 1 other company. Contact Info: 1 email address
- Aashish Manglik: Co-Founder of Stipple Bio. Contact Info: 1 email address
View details of Stipple Bio's Founder profiles and Board Members
Stipple Bio's employee count trend
Stipple Bio has 13 employees as of Apr 26. Here is Stipple Bio's employee count trend over the years:
Uncover Stipple Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Stipple Bio's Competitors and alternates
Top competitors of Stipple Bio include Evotec, Insitro and DNAnexus. Here is the list of Top 10 competitors of Stipple Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Provider of drug discovery alliance and development services for biopharma sector | $25M | 76/100 | ||
2nd |  Insitro 2018, San Francisco (United States), Series C | Developer of machine learning platform for drug discovery and development | $643M | 70/100 | |
3rd |  DNAnexus 2009, Mountain View (United States), Series H | Provider of cloud-based genome informatics & data management platform | $473M | 70/100 | |
4th | Cytel 1987, Cambridge (United States), Acquired | Provider of data analysis and statistical solutions for the life sciences industry | $2M | 67/100 | |
5th | Immunai Technologies 2018, United States, Series B | Developer of next-generation of immunomodulatory therapeutics | $295M | 66/100 | |
6th | Engine Biosciences 2014, Singapore (Singapore), Series A | Developer of platform technology for combinatorial genetics discovery | $86M | 66/100 | |
7th | Metagenomi 2016, Berkeley (United States), Public | Digital gene editing technologies for drug development | $376M | 65/100 | |
8th |  Asimov 2017, Boston (United States), Series B | Provider of integrated suite for advanced genetic design and manufacturing | $237M | 65/100 | |
9th |  NewLimit 2022, San Francisco (United States), Series B | Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension | $247M | 64/100 | |
10th | Creyon Bio 2019, San Diego (United States), Series A | Provider of drug design and oligonucleotide-based drug development platform | $40M | 64/100 | |
27th |  Stipple Bio 2021, Cambridge (United States), Series A | Provider of a platform that utilizes epitope-level resolution to unlock cellular profiling and target discovery | $109M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Stipple Bio's competitors? Click here to see the top ones
Stipple Bio's Investments and acquisitions
Stipple Bio has made no investments or acquisitions yet.
News related to Stipple Bio
Media has covered Stipple Bio for 1 event in last 1 year.
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Stipple Bio
Explore our recently published companies
- Fisher Design - Cincinnati based, 1958 founded, Unfunded company
- White Orchid Hospice - Sugar Land based, 2015 founded, Public company
- Willygoat - Birmingham based, 2000 founded, Unfunded company
- Nahdi - Saudi Arabia based, 1993 founded, Unfunded company
- Promus Advisors - Dallas based, 2011 founded, Unfunded company
- Divine Bridge For Humanity - Fayetteville based, 2024 founded, Unfunded company
